Daily Respiratory Research Analysis
Long-term outcomes from a phase 3 RCT show sugemalimab plus chemotherapy significantly improves 4-year survival in metastatic NSCLC versus chemotherapy alone. A randomized neonatal trial found that targeting higher permissive hypercapnia after day 7 increased ventilator-free days in preterm infants. Mechanistic work identifies FKBP5 as a driver of alveolar fibroblast necroptosis in ARDS, suggesting a new therapeutic target.
Summary
Long-term outcomes from a phase 3 RCT show sugemalimab plus chemotherapy significantly improves 4-year survival in metastatic NSCLC versus chemotherapy alone. A randomized neonatal trial found that targeting higher permissive hypercapnia after day 7 increased ventilator-free days in preterm infants. Mechanistic work identifies FKBP5 as a driver of alveolar fibroblast necroptosis in ARDS, suggesting a new therapeutic target.
Research Themes
- Immunotherapy plus chemotherapy in metastatic NSCLC with durable survival benefit
- Ventilation strategies in preterm infants: permissive hypercapnia
- ARDS pathobiology: FKBP5-driven necroptosis as a target
Selected Articles
1. Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
In treatment-naive metastatic NSCLC without actionable drivers, sugemalimab plus platinum-based chemotherapy significantly improved PFS and OS versus chemotherapy alone, with a 4-year OS rate of 32.1% versus 17.3%. Safety remained manageable with no new signals over extended follow-up.
Impact: This double-blind phase 3 RCT provides durable 4-year survival data supporting a first-line immunochemotherapy option across NSCLC histologies. It offers robust evidence relevant to guideline updates and treatment selection.
Clinical Implications: Sugemalimab plus platinum-based chemotherapy can be considered a standard first-line option for metastatic NSCLC without targetable alterations, offering significant survival gains with manageable toxicity.
Key Findings
- Median PFS improved to 9.0 months vs 4.9 months (HR 0.49).
- Median OS improved to 25.2 months vs 16.9 months (HR 0.68).
- 4-year OS rate was 32.1% with sugemalimab vs 17.3% with placebo.
- No new safety signals; grade 3–4 cytopenias were the most common adverse events.
Methodological Strengths
- Double-blind, randomized, phase 3 design with histology-specific regimens
- Long median follow-up (~43 months) enabling 4-year survival assessment
Limitations
- All participants were Asian and recruited in China, potentially limiting generalizability.
- Post-hoc reporting of 4-year outcomes; cross-over details not described.
Future Directions: Head-to-head comparisons with other PD-(L)1-based regimens and real-world effectiveness across diverse populations will clarify positioning; biomarker analyses may refine patient selection.
BACKGROUND: GEMSTONE-302 was a phase 3 trial in patients with treatment-naive metastatic squamous or non-squamous non-small-cell lung cancer (NSCLC), showed significant improvement in progression-free survival and overall survival with sugemalimab, a PD-L1 inhibitor, plus chemotherapy versus placebo plus chemotherapy. We report the 4-year outcomes from this study. METHODS: This randomised, double-blind, phase 3 trial was conducted across 35 hospitals and academic research centres in China. Eligible patients were aged 18-75 years; had treatment-naive, histologically or cytologically confirmed stage IV NSCLC, irrespective of PD-L1 expression levels; and had an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomised (2:1) by investigators using an interactive web response or voice response system via permuted blocks (block sizes of three or six, randomised within each stratum). Patients received histology-specific platinum-based chemotherapy combined with either sugemalimab (1200 mg; sugemalimab group) or placebo (placebo group) for up to four cycles, followed by for up to 35 cycles of maintenance therapy with sugemalimab alone for patients with squamous NSCLC and sugemalimab plus pemetrexed for patients with non-squamous NSCLC in the sugemalimab group, or placebo for patients with squamous NSCLC and placebo plus pemetrexed for patients with non-squamous NSCLC in the placebo group, administered intravenously. Treatment beyond 35 cycles was permitted at the investigator's discretion. The primary endpoint was investigator-assessed progression-free survival in the intention-to-treat population. Here, we report post-hoc 4-year efficacy and safety outcomes from GEMSTONE-302. This study is registered with ClinicalTrials.gov (NCT03789604) and concluded on May 15, 2023, with all patients discontinued. FINDINGS: Between December 13, 2018, and May 15, 2020, 846 patients were assessed for eligibility. 479 patients were randomly assigned into the sugemalimab group (n=320) and placebo group (n=159). 254 (79%) patients were men and 66 (21%) were women in the sugemalimab group and 129 (81%) were men and 30 (19%) were women in the placebo group. All patients were Asian. As of the data cutoff on May 15, 2023, median follow-up durations were 43·5 months (IQR 41·2-46·9) in the sugemalimab group and 43·0 months (40·7-44·8) in the placebo group; median treatment durations were 7·2 months (4·2-18·8) with sugemalimab and 4·6 months (2·8-6·9) with placebo. Median progression-free survival was 9·0 months (95% CI 7·4-10·9) in the sugemalimab group versus 4·9 months (4·8-5·2) in the placebo group (hazard ratio [HR] 0·49 [95% CI 0·39-0·60]). Median overall survival was 25·2 months (20·1-30·2) in the sugemalimab group versus 16·9 months (12·8-20·7) in the placebo group (HR 0·68 [0·54-0·85]). The 4-year overall survival rates were 32·1% (95% CI 26·7-37·6) in the sugemalimab group versus 17·3% (11·1-24·7) in the placebo group. The most common grade 3-4 treatment related adverse events were decreased neutrophil count (105 [33%] with sugemalimab vs 52 [33%] with placebo), decreased white blood cell count (48 [15%] vs 27 [17%]), anaemia (44 [14%] vs 18 [11%]), and decreased platelet count (35 [11%] vs 15 [9%]). Treatment-related serious adverse events occurred in 82 (26%) patients with sugemalimab and 31 (20%) with placebo. No additional treatment-related deaths occurred since the previous overall survival interim analysis. No new safety signals were identified. INTERPRETATION: Sugemalimab with chemotherapy showed a superior long-term overall survival benefit compared with placebo with chemotherapy, as a first-line treatment for patients with NSCLC with no known sensitising EGFR, ALK, ROS1, or RET genomic alterations. These results underscore the efficacy of sugemalimab plus platinum-based chemotherapy as a standard first-line treatment option for both squamous and non-squamous metastatic NSCLC while maintaining a manageable safety profile. FUNDING: CStone Pharmaceuticals. TRANSLATION: For the Chinese translation of the abstract see Supplementary Materials section.
2. Late Permissive Hypercapnia for Mechanically Ventilated Preterm Infants: A Randomized Trial.
In a single-center randomized trial of 130 preterm infants ventilated on postnatal days 7–14, targeting higher pH-controlled permissive hypercapnia (PaCO2 60–75 mmHg) increased ventilator-free days over 28 days compared with lower targets. Potential lung-protective benefits were observed without clear differences in BPD or death.
Impact: Provides randomized evidence on CO2 targeting after the first week of life, a common clinical dilemma in neonatal ventilation strategies with potential to reduce ventilation days.
Clinical Implications: For preterm infants ventilated beyond the first week, higher pH-controlled permissive hypercapnia targets may be considered to increase ventilator-free days, with careful monitoring of pH and CO2.
Key Findings
- Higher PaCO2 target (60–75 mmHg, pH≥7.20) increased ventilator-free days (11±10 vs 6±8; p=0.009).
- Randomized 1:1, 130 infants (mean GA ~24+5 weeks; mean BW 657 g).
- No clear reduction in grade 2–3 BPD or death before discharge.
Methodological Strengths
- Prospective randomized design with protocolized PaCO2/pH targets
- Clinically meaningful primary endpoint (28-day ventilator-free days)
Limitations
- Single-center study limits generalizability.
- Trial registration occurred after first enrollment, although authors report no protocol changes.
Future Directions: Multicenter trials to confirm safety and effects on BPD, neurodevelopment, and other long-term outcomes; integration with permissive oxygenation strategies.
OBJECTIVE: To determine if targeting higher levels of pH-controlled permissive hypercapnia beyond postnatal day 7-14 reduces mechanical ventilation duration in preterm infants. METHODS: Single-center randomized clinical trial with a 1:1 parallel allocation including infants from 22-36 weeks' gestation mechanically ventilated for respiratory distress syndrome on postnatal day 7-14. We targeted higher levels of pH-controlled permissive hypercapnia (60-75 mmHg and pH ≥ 7.20) or lower levels of pH-controlled permissive hypercapnia (40-55 mmHg and pH ≥ 7.25) for 28 days after randomization. The primary outcome was the number of days alive and ventilator-free in the 28 days after randomization. RESULTS: We enrolled 130 infants with a gestational age (mean ± SD) of 24 weeks and 5 days ± 2 weeks and 0 days and birth weight of 657 ± 198 grams from December 2015 to May 2021. Infants randomized to higher levels of pH-controlled permissive hypercapnia had more alive ventilator-free days than infants randomized to lower levels of pH-controlled permissive hypercapnia (11 ± 10 vs. 6 ± 8; p = 0.009). Grade 2-3 bronchopulmonary dysplasia or death before discharge was not significantly lower in the higher carbon dioxide (PCO CONCLUSIONS: Targeting higher levels of permissive hypercapnia from postnatal day 7-14 increased the number of days alive and ventilator-free and may be lung protective compared with targeting lower levels. TRIAL REGISTRATION: Clinicaltrials.gov (identifier number NCT02799875). The first infant was enrolled in December 2015 and the trial was not registered until June 2016. The authors confirm that there were no changes made to the Institutional Review Board (IRB) approved trial protocol (dated 10/20/2015) or any amendments made after recruitment started, between the date of first enrollment and the date of clinicaltrials.gov registration, or between study commencement and completion. Furthermore, the authors confirm that the data were not unblinded until after the last infant had been enrolled (March 2021) and discharged from the hospital (August 2021). Study Details | Late Permissive Hypercapnia for Intubated and Ventilated Preterm Infants | ClinicalTrials.gov.
3. FKBP5 Mediates Alveolar Fibroblast Necroptosis During Acute Respiratory Distress Syndrome.
FKBP5 was upregulated in sepsis and correlated with cytokines and severity, and mechanistic experiments demonstrated FKBP5 drives necroptosis in alveolar fibroblasts in sepsis-induced ARDS models. These data implicate FKBP5 as a key mediator of parenchymal injury and a potential therapeutic target in ARDS.
Impact: Identifies a mechanistic link between stress signaling and necroptotic cell death in lung parenchyma, addressing a major therapeutic gap in ARDS.
Clinical Implications: While preclinical, FKBP5 inhibition could attenuate fibroblast necroptosis and downstream lung injury in ARDS; it motivates drug discovery and biomarker development.
Key Findings
- FKBP5 expression is markedly increased in sepsis and correlates with cytokine levels and disease severity.
- In sepsis-induced ARDS models, FKBP5 mediates necroptosis in alveolar fibroblasts.
- Data highlight FKBP5 as a mechanistic driver of lung parenchymal injury and a potential therapeutic target.
Methodological Strengths
- Human correlation of FKBP5 with sepsis severity and cytokines
- In vivo mechanistic ARDS models with genetic manipulation of Fkbp5
Limitations
- Abstracted details on sample sizes and specific necroptosis pathways are not provided in the summary.
- Translational relevance requires pharmacologic validation and safety assessment.
Future Directions: Evaluate FKBP5 inhibitors in ARDS-relevant preclinical models; define cell-type specificity and pathway interactions; develop clinical biomarkers for patient stratification.
The inflammatory storm is a hallmark of acute respiratory distress syndrome (ARDS), yet effective therapies remain unavailable. FK506-binding protein 51 (FKBP5) has emerged as a regulator of inflammatory responses. In this study, FKBP5 expression was markedly increased in patients with sepsis and correlated with both cytokine levels and disease severity. Using sepsis-induced ARDS models in Fkbp5